Volume 6, Issue 2 (12-2019)                   vacres 2019, 6(2): 42-46 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Verma N, Bimal S, Gupta Anil K, Lal C, Ranjan A, Verma R, et al . A Community Based Cohort Study on Usefulness of Leishmanin Skin Test in Detection of Immunoreactivity Against Leishmania donovani Infection in an Endemic Area of Kala-Azar, Bihar, India. vacres 2019; 6 (2) :42-46
URL: http://vacres.pasteur.ac.ir/article-1-168-en.html
ICMR-RMRIMS
Abstract:   (1569 Views)
A B S T R A C T
Introduction: Control efforts of visceral leishmaniasis (VL) are hindered due to inappropriate early case detection of Leishmania infection with varying degree of susceptibility to develop the disease. Methods: We assessed the current infection status using Leishmanin skin test (LST) and direct agglutination test (DAT) in a cohort population (206 randomly selected individuals) in a VL endemic area of Bihar, India. Results: Cellular immunity was revealed in 18.4% and antibody response in 18.9% of the population. The age-group of 20-29 years were most vulnerable. DAT titer was inversely proportional to duration of past history of VL. The houses having present or past history of kala-azar in family were observed with high Leishmanin and DAT positivity, indicating relevance of household contacts in the disease transmission. Conclusion: The reactivity of both LST and DAT tests may help in identifying the possible groups with varying degree of susceptibility and risk of infection or having prior exposure to the leishmania infection with or without development of the disease.
Full-Text [PDF 352 kb]   (488 Downloads)    
Type of Study: Research | Subject: Infectious diseases
Received: 2020/01/21

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.